AACR: Immunotherapy pioneer James P. Allison, Ph.D., honored with Award for Lifetime Achievement in Cancer Research

Top honor from AACR recognizes Nobel laureate for lifelong commitment to scientific discovery and seminal findings that launched the field of cancer immunotherapy

MD Anderson News Release April 13, 2026

James P. Allison, Ph.D., Regental professor and chair of Immunology, vice president of immunobiology and founding director of the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center, will be honored with the American Association of Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research at the AACR Annual Meeting 2026. The distinguished honor recognizes Allison’s lifelong contributions to advancing groundbreaking research that helped launch the field of cancer immunotherapy.

With this honor, Allison joins past honorees recognized for significant fundamental contributions to cancer research, either through a single scientific discovery or a body of work. The award celebrates the work of those who have created a lasting impact on the field of oncology, either through research, leadership or mentorship, demonstrating a lifetime commitment to progress against cancer. Allison will be awarded and will present his lecture on April 19.

“We congratulate Dr. Allison on this tremendous achievement and testament to his life’s work, resulting in invaluable contributions to the field of cancer research,” said Peter WT Pisters, M.D., president of UT MD Anderson. “His pioneering work transformed cancer care, creating a new pillar of cancer therapy and bringing cures to countless patients. His research exemplifies our institution’s continued pursuit of exceptional science to advance our mission to end cancer.”

Allison was awarded the 2018 Nobel Prize in Physiology or Medicine jointly with Tasuku Honjo, M.D., Ph.D., for fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer. These seminal discoveries launched the field of cancer immunotherapy, which today represents a standard therapeutic option for many cancer types.

Allison’s career has been dedicated to studying the regulation of T cell responses and developing new therapeutic strategies for cancer immunotherapy. Among his most notable discoveries are the T cell receptor structure and the determination that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. Allison’s lab resolved a major controversy in the field by demonstrating that CTLA-4 inhibits T cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models.

He proposed that blockade of immune checkpoints such as CTLA-4 may be a powerful strategy for therapy of many cancer types, and he conducted preclinical experiments showing its potential. This work led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the Food and Drug Administration. Since that time, ipilimumab has been approved as part of the therapeutic regimen for multiple cancer types.

In 2022, UT MD Anderson launched the Allison Institute, which aims to build upon the legacy of its namesake. Allison serves as the founding director of the institute, which seeks to integrate science from multiple disciplines to bring the promise of immunotherapy to more patients with a wider range of cancers.

“It is an honor to be recognized for my life’s work, and I receive this award with gratitude for my colleagues, this community of researchers and the patients we strive to help every day,” Allison said. “This recognition reaffirms my commitment to discovery science, lifelong learning and collaboration to bring cures to many more patients.”

Allison earned his doctoral degree from The University of Texas at Austin and completed postgraduate work at Scripps Clinic and Research Foundation in La Jolla, California, where he served as a postdoctoral fellow. He first joined UT MD Anderson in 1977 as a researcher at the institution’s Smithville, Texas, research center. Supported by a grant from the Cancer Prevention and Research Institute of Texas, Allison was recruited back to UT MD Anderson in November 2012 to lead the Department of Immunology and to establish an immunotherapy research platform.

“Dr. Allison’s lifetime commitment to advancing breakthrough research is a tremendous asset for UT MD Anderson and the scientific community,” said Albert Koong, M.D., Ph.D., chief scientific officer at UT MD Anderson. “AACR’s recognition of his work is a timely and meaningful acknowledgement of Dr. Allison’s scientific rigor, commitment to collaborative research and translational focus to bring the benefits of immunotherapy to all patients.”

AACR has previously honored Allison with the inaugural AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology and as a Fellow of the AACR Academy. He also is a member of both the National Academies of Sciences (NAS) and Medicine. In addition to the Nobel Prize, Allison has been recognized with the Breakthrough Prize in Life Sciences, the Lasker-DeBakey Clinical Medical Research Award, the Szent-Györgi Prize for Progress in Cancer Research, the Balzan Prize for Immunological Approaches in Cancer Therapy, the Jessie Stevenson Kovalenko Medal from the NAS, the The King Faisal Prize in Medicine, and the Banco Bilbao Vizcaya Argentaria (BBVA) Foundation Frontiers of Knowledge Award.

More information on all UT MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR.